Therefore, we proposed the mRNA expression level of AURKA to possibly be a useful standard for identifying and selecting WJ-MSCs for the development and manufacture of cell therapy products for DMD treatment. The gene discussed is AURKA; the disease is Duchenne muscular dystrophy.